Spero Therapeutics, Inc.
SPRO
$0.7542
$0.01421.92%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -53.77% | 37.01% | 118.43% | 107.40% | 93.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.77% | 37.01% | 118.43% | 107.40% | 93.95% |
| Cost of Revenue | 95.90% | 166.67% | 122.56% | 94.17% | 44.02% |
| Gross Profit | -302.20% | -64.92% | 105.72% | 145.06% | 495.64% |
| SG&A Expenses | -7.24% | -9.90% | -11.11% | -15.23% | -29.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.46% | 42.30% | 44.64% | 23.28% | -8.42% |
| Operating Income | -370.59% | -152.27% | 257.49% | 285.32% | 187.63% |
| Income Before Tax | -369.90% | 504.69% | 298.86% | 196.83% | 154.73% |
| Income Tax Expenses | -100.00% | -95.61% | -- | -- | -- |
| Earnings from Continuing Operations | -400.65% | 317.66% | 273.10% | 187.16% | 149.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -400.65% | 317.66% | 273.10% | 187.16% | 149.13% |
| EBIT | -370.59% | -152.27% | 257.49% | 285.32% | 187.63% |
| EBITDA | -366.60% | -137.87% | 266.94% | 298.48% | 191.43% |
| EPS Basic | -397.61% | 756.84% | 232.26% | 149.19% | 125.77% |
| Normalized Basic EPS | -317.34% | -44.86% | 287.04% | 235.76% | 148.38% |
| EPS Diluted | -400.33% | 696.84% | 230.03% | 148.55% | 125.58% |
| Normalized Diluted EPS | -318.07% | -46.13% | 286.30% | 235.32% | 148.22% |
| Average Basic Shares Outstanding | 2.53% | 3.91% | 12.39% | 24.52% | 40.37% |
| Average Diluted Shares Outstanding | 2.48% | 3.97% | 12.44% | 24.58% | 40.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |